AbbVie Health Press Releases — RSS Feed & Live Monitoring
PPN World tracks the AbbVie RSS feed in real time — 5 releases indexed over the last 30 days, the newest arrived 4 h ago. Follow it with saved-search alerts, AI summaries, and full-text search, or plug the RSS URL below into your own reader.
AbbVie RSS feed URL
https://news.abbvie.com/index.php?s=2429&pagetemplate=rssAbout this feed
AbbVie is one of the 1200+ press-release feeds PPN World monitors around the clock — an English-language wire focused on Health, filed under United States in our country index. Every release is deduplicated, geotagged, and enriched with an AI summary, and you can attach saved-search alerts to any keyword it publishes. AbbVie is a low-volume specialist wire — 5 releases over the last 30 days: the kind of source worth an alert rather than a scroll.
How to follow AbbVie press releases
- Copy the AbbVie RSS feed URL shown above.
- Paste it into any RSS reader (Feedly, Inoreader, NetNewsWire…) to get the raw feed.
- Or track AbbVie in PPN World to add deduplication, saved-search alerts, and AI summaries across all 1200+ wires.
Latest AbbVie press releases
- JUVÉDERM® Day Returns to U.S. on August 194 h ago
Allergan Aesthetics celebrates fourth annual JUVÉDERM ® Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first...
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata1 d ago
RINVOQ® is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA) Approval was based on the pivotal Phase 3 UP-AA clinical program, whic…
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo1 d ago
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phas…
- Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)6 d ago
COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026 Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE® DLBCL-1 trial and was not met...
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients13 d ago
Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹...
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development16 d ago
SkinMedica® launches Regenerative Science Advisory Board to shape future innovation Expands its state-of-the-art research and development (R&D) facility to support the next generation of...
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma23 d ago
TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory follicular lymphoma in...
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma30 d ago
Topline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in...
- AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata31 d ago
Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score ≤ 20 and key...
The newest releases on this wire stream live for PPN World members.